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risk thresholds (FNRTs) for primary prophylaxis with
CSFs.
OBJECTIVES: To determine the impact of CPMs on
FNRT estimates with the CSFs.
METHODS: Cost-minimization models based on stan-
dard decision theory were generated, incorporating 1)
probabilities and resource utilization from randomized
clinical trials and 2) unit cost information from local in-
stitutional sources. Sensitivity analyses were performed,
varying resource use, costs, and test performance charac-
teristics. FNRTs were derived at which cost equivalence
was reached in each model. The test performance of pos-
sible CPMs was assessed utilizing the likelihood ratio
(LR) for discriminating high-risk patients with probabil-
ity (prob[HR]).
RESULTS: Baseline cost-minimization models were
equated with CPMs with a LR  1.0. The FNRT for CSF
use decreases as hospitalization length of stay (LOS) or
cost/day increase. Any CPM associated with a LR
1
generates lower FNRTs than under baseline conditions.
Test efficiency of the CPMs improves with increasing
LR
, with optimal performance observed between 2.0
and 4.0. In balanced CPMs with LR
  3.0, FNRTs are
reached for costs/day of $1000, $1500, and $2000 at
0.21, 0.16, and 0.13 respectively. In unbalanced CPMs,
FNRTs are 10% at prob(HR)  0.4, 0.3, 0.2, and 0.1
at costs/day of $1700, $1000, $600, and $300, respec-
tively. 
CONCLUSIONS: Efficient CPMs to identify high-risk pa-
tients should be able to further reduce costs and FNRTs
for CSF use based on cost-minimization.
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OBJECTIVE: To evaluate the QoL of Ig-NHL patients
enrolled in a trial comparing the efficacy and safety of F
and CVP.
METHODS: The EORTC-QLQ-C30 (v1) questionnaire
was completed by all French- and English-literate patients
at baseline, during treatment, and after treatment. QoL
was expressed as a global health status (QL) and five
functional scores (FS); physical, emotional, social (SF), cog-
nitive (CF) and role (RF), for which high values indicate
better QoL. It was also expressed as eight symptom/single
item (SSI) scores: fatigue, nausea, and vomiting (NV),
pain, dyspnea (DY), insomnia, appetite loss, constipation
(CO), diarrhea (DI), and financial difficulties (FI) for
which lower values mean better QoL.
RESULTS: Of the 91 patients recruited (F  47, CVP 
44), 84 completed the questionnaire at baseline, 74 dur-
ing treatment, and 41 after treatment. All FS were high at
baseline (70–90) and varied from 1 to 12 points during
the study. All FS improved during treatment except CF
and QL in the F group, which remained unchanged; and
RF and SF in the CVP group, which deteriorated. The dif-
ference between groups reached statistical significance for
SF (p  0.0076) but not for RF (p  0.4597). All SSI
scores were low (10 to 40) and varied only slightly during
the trial. Most scores improved except DY and CO in the
F group and NV, CO, DI, and FI in the CVP group. 
CONCLUSIONS: QoL was high in these patients. The
higher incidence of nausea, vomiting, and alopecia ob-
served in the CVP group may explain the difference ob-
served for SF, and, to a lesser extent, RF.
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OBJECTIVE: The objective of this study was to deter-
mine the relationship between profile-based cancer-spe-
cific quality of life dimension scores, and EuroQol-5D
scores in a breast cancer surgery sample.
METHODS: Seventy-five breast cancer surgery patients
participated in the study. The patients completed the Func-
tional Living Index-Cancer (FLIC), the Functional Assess-
ment of Cancer Therapy-General Version (FACT-G), and
the EuroQol-5D (EQ-5D) at the same visit, and the order
of instruments was randomized. Scores on both the EQ-5D
classification system, as well as on the thermometer, were
obtained, and both scores were related to dimension scores
on the FLIC and the FACT-G. Information on the age of
the patient, the cancer stage, and the number of comorbid-
ities was obtained through chart review.
RESULTS: The mean age of patients was 60 (SD  10.7).
The majority of patients (96%) were diagnosed with ei-
ther stage I or stage II breast cancer. Over 90% of pa-
tients had up to three comorbid conditions, with hyperten-
sion being the most frequent. Mean scores on the EQ-5D
classification system and the thermometer were 87.4
(SD  13.6), and 86.6 (SD  12.6), respectively. Ceiling
effects were observed on the classification system as well
as the thermometer. Both linear and double log regres-
sion results showed that quality of life dimension scores
were significantly related to scores in both the EQ-5D
classification systems and the thermometer. FLIC dimen-
sion scores made statistically significant contributions to
the EQ-5D classification score, but not to the score ob-
tained on the thermometer. FACT-G dimension scores
did not contribute significantly to either the EQ-5D clas-
sification score or to the thermometer score.
CONCLUSION: The results of this study show that can-
